Investors tend to jump from one hot investment idea to another. Right now, GLP-1 drugs are the hot story, and this pharmaceutical giant isn't even in the game yet.

JNJ's diversified pharma and MedTech growth, pipeline progress and stronger 2026 outlook give it an edge over PFE.

Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

PFE's aggressive M&A and in-house R&D efforts are paying off, with the growth portfolio (newly launched/acquired products) already delivering $3.1B in revenues in FQ1'26 (+22% YoY operationally). LOE risks are mitigated by delayed Vyndamax generic entry to mid-2031, supporting the management's high single-digit 5Y revenue growth guidance from 2029 onwards. PFE's intermediate-term performance is expected to remain lumpy, but the cost saving efforts, strong interest coverage, and dividend sustainability underpin its compelling investment thesis.

Pfizer (PFE) is trying to defend one of its most important vaccine franchises with a next-generation version of Prevnar, after early trial data suggested the ex

Johnson & Johnson offers a superior return/risk profile versus Pfizer, driven by consistency and operational stability. PFE's far lower valuation (FWD P/E 8.55x, PEGY 0.97x) and far higher yield (6.79%) are certainly attractive. But JNJ's 63-year streak of dividend growth, lower payout ratio (48.46%), ongoing buybacks, and stable inventory all point to far superior consistency.

PFE bets on Padcev, biosimilars and late-stage pipeline candidates to drive long-term oncology growth amid pressure on legacy drugs.

NASHVILLE, Tenn.--(BUSINESS WIRE)--Sarah Cannon Research Institute (SCRI), one of the world's leading oncology research organizations conducting community-based clinical trials, today announced a strategic collaboration with Pfizer Inc. to advance the development of Pfizer's oncology portfolio through a science‑driven and scaled research program designed to bring promising therapies to patients faster and closer to home. Central to the collaboration is SCRI's Accelero™, a next-generation clinic.

Pfizer said on Wednesday its experimental pneumococcal vaccine showed significantly stronger immune response than its current shot, including up ​to 15-fold higher antibody levels against a key strain, ‌in a mid-stage study.

The next-generation version of Pfizer's $6 billion pneumococcal vaccine franchise topped its predecessor in a midstage study.